Journal of Diagnostics Concepts & Practice >
Correlation of KIT and PDGFRA mutation status with clinicopathologic features in primary and recurrent or metastatic gastrointestinal stromal tumors
Received date: 2021-03-20
Online published: 2022-06-28
Objective: To investigate the correlation of KIT and PDGFRA mutation status with immunohistochemistry (IHC) and clinicopathological features in the primary, recurren tor metastatic gastrointestinal stromal tumors (GIST). Methods: A total of 167 primary GIST including 22 recurrent or metastatic GIST were tested for CD117, DOG1, CD34 and Ki-67 by IHC, and KIT gene exon 9, 11, 13, 17and PDGFRA gene exon12, 18 were analyzed by Sanger sequencing. Results: The frequencies of KIT and PDGFRA mutation in 167 primary GIST were 83.8%(140/167) and 3.0% (5/167), respectively. The mutation frequencies of KIT gene exon 11, exon 9 and exon 17 were 74.9% (125/167),8.4% (14/167) and 0.6% (1/167). Five primary GIST harbored PDGFRA mutations in exon 18,and 4 tumors had D842V mutation. Genetic mutations in KIT gene included point mutations (34.3%,48/140), deletion mutations (40.7%,57/140), duplication mutations (3.6%,5/140), and complicated mutations (deletion-insertion,12.1%,17/140).For GIST with KIT gene exon 11 mutation, Ki-67 index was significantly higher in tumors with non-point mutation than those with point mutations (P=0.0052). In 22 recurrent or metastatic GIST, double-exon mutation on KIT gene were found in 9 cases and 6 case were with mutation in both exon 11 and 17, 2 in exon 11 and 13,and one in exon 9 and 13.In 22 cases with recurrent or metastatic GIST, patients with double KIT exon mutations had a longer median progression-free survival (PFS)(108 months) than those with wild type gene (PFS, 30 months),and single exon mutation (PFS, 60 months)(P=0.0299 and P=0.0111), while no significant difference were observed regarding Ki-67, CD117, DOG1, CD34 expression,tumor size and nuclear mitosis between them. Conclusions: KIT mutations in primary GIST occur more often in exon 11. For primary GIST with KIT exon 11 mutations, Ki-67 index is higher in lesions with non-point mutation than those with point mutation,indicating poor biological beha-vior. In recurrence or metastatic GIST, cases harbor the double KIT exon mutations account for 9/22 and possess a better PFS than those with wild type and singe KIT exon 11 mutation.
GU Yijin, LI Anqi, DONG Lei, XU Haimin, SHEN Xia, XIE Jialing, YUAN Fei, WANG Chaofu . Correlation of KIT and PDGFRA mutation status with clinicopathologic features in primary and recurrent or metastatic gastrointestinal stromal tumors[J]. Journal of Diagnostics Concepts & Practice, 2021 , 20(03) : 257 -264 . DOI: 10.16150/j.1671-2870.2021.03.006
[1] | Joensuu H, Hohenberger P, Corless CL. Gastrointestinal stromal tumour[J]. Lancet, 2013, 382(9896):973-983. |
[2] | Corless CL. Gastrointestinal stromal tumors: what do we know now?[J]. Mod Pathol, 2014, 27(Suppl 1):S1-S16. |
[3] | 徐佳, 赵文毅, 庄淳, 等. 胃肠道间质瘤术后伊马替尼辅助治疗停药后复发的危险因素分析[J]. 中国普通外科杂志, 2016, 31(2):104-107. |
[4] | Shen YY, Ma XL, Wang M, et al. Exon 11 homozygous mutations and intron 10/exon 11 junction deletions in the KIT gene are associated with poor prognosis of patients with gastrointestinal stromal tumors[J]. Cancer Med, 2020, 9(18):6485-6496. |
[5] | Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors[J]. N Engl J Med, 2002, 347(7):472-480. |
[6] | Nishida T, Blay JY, Hirota S, et al. The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines[J]. Gastric Cancer, 2016, 19(1):3-14. |
[7] | Debiec-Rychter M. Sunitinib--a new approach following failure of imatinib in patients with advanced gastrointestinal stromal tumor[J]. Nat Clin Pract Oncol, 2007, 4(6):342-343. |
[8] | Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship[J]. Clin Cancer Res, 2003, 9(1):327-337. |
[9] | Demetri GD, Reichardt P, Kang YK, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial[J]. Lancet, 2013, 381(9863):295-302. |
[10] | George S, Jones RL, Bauer S, et al. Avapritinib in Patients With Advanced Gastrointestinal Stromal Tumors Following at Least Three Prior Lines of Therapy[J]. Oncologist, 2021, 26(4):e639-e649. |
[11] | Falkenhorst J, Hamacher R, Bauer S. New therapeutic agents in gastrointestinal stromal tumours[J]. Curr Opin Oncol, 2019, 31(4):322-328. |
[12] | Joensuu H, DeMatteo RP. The management of gastrointestinal stromal tumors: a model for targeted and multidisciplinary therapy of malignancy[J]. Annu Rev Med, 2012, 63:247-258. |
[13] | 中国胃肠道间质瘤病理共识意见专家组. 中国胃肠道间质瘤诊断治疗专家共识(2017年版)病理解读[J]. 中华病理学杂志, 2018, 47(1):2-6. |
[14] | 许海敏, 陈晓炎, 董磊, 等. 不同克隆号 ALK 抗体在炎性肌纤维母细胞肿瘤中的表达比较研究[J]. 诊断病理学杂志, 2020, 27(9):629-632,636. |
[15] | Sihto H, Sarlomo-Rikala M, Tynninen O, et al. KIT and platelet-derived growth factor receptor alpha tyrosine kinase gene mutations and KIT amplifications in human solid tumors[J]. J Clin Oncol, 2005, 23(1):49-57. |
[16] | Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor[J]. Hum Pathol, 2008, 39(10):1411-1419. |
[17] | Nannini M, Tarantino G, Indio V, et al. Molecular mode-lling evaluation of exon 18 His845_Asn848delinsPro PDGFRα mutation in a metastatic GIST patient respon-ding to imatinib[J]. Sci Rep, 2019, 9(1):2172. |
[18] | Wang M, Xu J, Zhao W, et al. Prognostic value of mutational characteristics in gastrointestinal stromal tumors: a single-center experience in 275 cases[J]. Med Oncol, 2014, 31(1):819. |
[19] | Wozniak A, Rutkowski P, Schöffski P, et al. Tumor genotype is an independent prognostic factor in primary gastrointestinal stromal tumors of gastric origin: a european multicenter analysis based on ConticaGIST[J]. Clin Cancer Res, 2014, 20(23):6105-6116. |
[20] | Martin-Broto J, Gutierrez A, Garcia-Del-Muro X, et al. Prognostic time dependence of deletions affecting codons 557 and/or 558 of KIT gene for relapse-free survival (RFS) in localized GIST: a Spanish Group for Sarcoma Research (GEIS) Study[J]. Ann Oncol, 2010, 21(7):1552-1557. |
[21] | 中国临床肿瘤学会胃肠间质瘤专家委员会. 中国胃肠间质瘤诊断治疗共识(2017年版)[J]. 肿瘤综合治疗电子杂志, 2018, 4(1):31-43. |
[22] | Artigiani Neto R, Logullo AF, Stávale JN, et al. Ki-67 expression score correlates to survival rate in gastrointestinal stromal tumors(GIST)[J]. Acta Cir Bras, 2012, 27(5):315-321. |
[23] | 朱从波, 廖国庆, 赵丁民. Ki-67对胃肠道间质瘤预后的评估价值[J]. 临床与病理杂志, 2018, 38(8):1632-1639. |
[24] | Heinrich MC, Rankin C, Blanke CD, et al. Correlation of long-term results of imatinib in advanced gastrointestinal stromal tumors with next-generation sequencing results: analysis of Phase 3 SWOG Intergroup Trial S0033[J]. JAMA Oncol, 2017, 3(7):944-952. |
[25] | Vanden Bempt I, Vander Borght S, Sciot R, et al. Comprehensive targeted next-generation sequencing approach in the molecular diagnosis of gastrointestinal stromal tumor[J]. Genes Chromosomes Cancer, 2021, 60(4):239-249. |
[26] | 孟琳, 张声. KIT基因双突变在胃肠道间质瘤中的作用[J]. 临床与病理杂志, 2018, 38(4): 830-836. |
[27] | Bosbach B, Deshpande S, Rossi F, et al. Imatinib resistance and microcytic erythrocytosis in a KitV558Δ;T669I/+ gatekeeper-mutant mouse model of gastrointestinal stromal tumor[J]. Proc Natl Acad Sci U S A, 2012, 109(34):E2276-E2283. |
[28] | Kang DY, Park CK, Choi JS, et al. Multiple gastrointestinal stromal tumors: clinicopathologic and genetic analysis of 12 patients[J]. Am J Surg Pathol, 2007, 31(2):224-232. |
[29] | Xu C, Liu YL, Yu HY, et al. Synchronous and metachronous multiple gastrointestinal stromal tumors[J]. Histol Histopathol, 2012, 27(2):225-234. |
/
〈 |
|
〉 |